All News Archive — Page 1 of 164

Mónica Santisteban, PhD
August 21, 2026

Vanderbilt Health’s Mónica Santisteban to be honored by the American Heart Association

The recognition honors her research that has helped define how high blood pressure can contribute to cognitive impairment and Alzheimer’s disease.

Jordyn Bugarin, 22, was the only patient in the United States enrolled in the OPTIMA clinical trial for fibrodysplasia ossificans progressiva (FOP), a rare genetic condition that causes muscle and connective tissue to turn into bone. (photo by Erin O. Smith)
August 20, 2026

Her muscles are slowly turning to bone. She was the only American in a trial that might stop it.

As part of the clinical trial, Jordyn Bugarin regularly traveled to Vanderbilt Health, navigating a complex study while living with a disease that can flare unpredictably and permanently limit movement. The experimental drug received federal approval on Aug. 19.

Karen Keady, PhD, RN, NEA-BC
August 20, 2026

Karen Keady to leave Vanderbilt Health for new leadership role at Mass General Brigham

Keady has been appointed inaugural Chief Nurse Executive at Mass General Brigham and will depart Vanderbilt Health in October. Pat Givens, DHA, RN, NEA-BC, will provide interim executive nursing leadership across the Vanderbilt Health system.

August 18, 2026

As schedules change, health care advocates encourage back seat second looks to prevent hot car deaths

It only takes 10 minutes for the temperature inside a vehicle to rise 19 degrees and continue to rise. Even on cooler days closer to 70 degrees, children can experience vehicular heatstroke.

August 18, 2026

Clinical Infusion Workgroup drives access, convenience and growth in patient care

Team lands award for expanding access points, streamlining processes and connecting patients to infusion care closer to home.

August 18, 2026

Could GLP-1s help treat opioid use disorder? Vanderbilt Health study now enrolling

The study, Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB), is a double-blind, randomized, placebo-controlled trial conducted through the National Institute on Drug Abuse’s Clinical Trials Network.